glutathione atherosclerosis system enhancement for cardiac protection: pharmacological options against oxidative stress and ferroptosis Frontiers | Clinical Advances in

Cancer Letters 225:1-26

Nle1-AngIV and Dihexa stimulated hippocampal neurons were immunostained against the glutamatergic presynaptic marker VGLUT1 (Balschun, Moechars et al

But it is worth being precise: these are proposed and studied mechanisms, not settled clinical facts

Peptides: Tesamorelin, AOD9604, Tirzepatide (GLP-1 agonist) Tesamorelin is FDA-approved to reduce visceral adipose tissue (VAT) in HIV-associated lipodystrophy, but its fat-burning effects also appear in non-HIV populations AOD9604 is a modified fragment of human GH (176191) shown in animal and early human trials to enhance lipolysis without altering blood sugar or cortisol Tirzepatide , while technically a GLP-1/GIP agonist , is now frequently stacked with peptides in clinical practice to accelerate fat loss and appetite control

A separate 2025 narrative review by McGuire and colleagues asked a blunter question in its title: "Regeneration or Risk?" [2] Their conclusion: the preclinical evidence is consistently positive, but the absence of human data makes it impossible to generate evidence-based practice guidelines